Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

Class I antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 0.13 [0, 6.57]
1 study · 212 participants
Very low

Class I and/or III antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 1 [0.06, 16.24]
1 study · 90 participants
Low

Interrupted vs uninterrupted anticoagulation therapy

All‐cause mortality · adults with arrhythmias undergoing catheter ablation

Interrupted showed no clear difference in all‐cause mortality compared with uninterrupted anticoagulation therapy (low certainty).

1 finding from 1 review

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 2021 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.21]
1 study · 442 participants
Low

Microwave coagulation vs radiofrequency ablation

All‐cause mortality · people with liver metastases

It is very uncertain whether microwave coagulation changes all‐cause mortality compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Microwave coagulation for liver metastases 2024 · Cochrane Headline outcomes only
RR 0.62 [0.26, 1.47]
1 study · 50 participants
Very low

Interrupted vs uninterrupted anticoagulation therapy

Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality · adults with arrhythmias undergoing catheter ablation

Interrupted may leads to lower composite endpoint of thromboembolic events (stroke or systemic… compared with uninterrupted anticoagulation therapy (low certainty).

1 finding from 1 review

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 2021 · Cochrane Headline outcomes only
RR 0.23 [0.07, 0.81]
1 study · 442 participants
Low

Surgery vs radiofrequency ablation

All‐cause mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery

It is very uncertain whether surgery changes all‐cause mortality at maximal compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
HR 0.8 [0.6, 1.08]
4 studies · 574 participants
Very low